News and Announcements
The Pulse appoints new Chief Medical Officer
- Published July 11, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- The Pulse appoints Dr Mark Hohenberg as Chief Medical Officer.
- Dr Hohenberg will head the company’s effort to integrate cutting-edge technologies into the healthcare and education sectors.
The Pulse has announced the appointment of Dr Mark Hohenberg as the Chief Medical Officer. The company aims to deliver world-class communication using technology platforms such as virtual reality (VR) and augmented reality (AR). The appointment of a senior clinician and academic to lead the healthcare technology integration projects is considered an Australian first. Hohenberg, an academic geriatric physician with roles at Campbelltown Hospital and Western Sydney University clinical Dean, will oversee the company’s development and integration of products for the healthcare and health professional education markets.
The decision to join an agency such as The Pulse which focuses on communication is unusual for a healthcare professional. Dr Hohenberg believes that the breakthroughs and efficiency that can be made by technology platforms will be ground-breaking and contribute to healthcare globally. The Pulse and Dr Hohenberg will work to incorporate VR and AR in healthcare to highlight the changing culture towards digitisation for efficiency in healthcare.
About the Pulse IQ
The Pulse IQ is a world first, device-agnostic platform for the delivery of immersive and collaborative Virtual Reality content for training and education.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
